I think that after Viread goes generic, payors can push to use in first line a one-pill-all-generic regimen of generic Sustiva and another generic NRTI and this will make life harder for branded regimens that are not superior.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.